Modulating immune responses and inflammatory factors in SSc via inhibition of the IFIT3/TBK1 signalling pathway: in vivo evidence from a CRISPR/Cas9‐edited mouse model. This evidence concerns the gene IFIT3 and systemic sclerosis.